Italia markets closed

Eterna Therapeutics Inc. (ERNA)

NasdaqCM - NasdaqCM Prezzo differito. Valuta in USD.
Aggiungi a watchlist
2,0201-0,1399 (-6,48%)
Alla chiusura: 04:00PM EDT
2,0200 -0,00 (-0,00%)
Dopo ore: 05:42PM EDT
Schermo intero
Caricamento grafico interattivo in corso...
  • GlobeNewswire

    Eterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Lineage Cell Therapeutics

    mRNA cell engineering strategically targets genes to create novel and potentially superior product profiles for cell transplant therapy applications Novel engineered iPS cell line to be evaluated by Lineage for potential development of cell transplant therapies for central nervous system diseases under collaboration initiated in early 2023 Lineage to make milestone payments to Eterna in connection with Eterna’s successful development and delivery to Lineage of certain materials CAMBRIDGE, Mass.,

  • GlobeNewswire

    Eterna Therapeutics Appoints Biopharma Industry Veteran Dorothy Clarke to Board of Directors

    Dorothy Clarke Dorothy Clarke CAMBRIDGE, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the appointment of Dorothy Clarke to its Board of Directors. “We are delighted to welcome Dorothy to our Board,” said Matt Angel, Ph.D., Chief Executive Officer and President of Eterna. “Dor

  • GlobeNewswire

    Eterna Therapeutics Announces Completion of $8.7 Million of Convertible Debt Financing

    CAMBRIDGE, MASS., July 18, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the execution and closing of the sale of approximately $8.7 million aggregate principal amount of senior convertible promissory notes and accompanying warrants to purchase common stock in a private placement transaction t